Exozymes Inc.EXOZ

Exozymes Inc. (CIK 2010788) filed an 8-K on 1 July 2026 to confirm the company’s enzymatic platform is advancing, but the accompanying 10-Q for the quarter ended 31 March 2026 shows a company haemorrhaging cash rather than haemoglobin. Net income attributable to parent was a loss of $2.4 million, operating loss was $2.4 million, and diluted earnings per share were minus 28 cents on 8.5 million diluted shares. Cash and equivalents stood at $1.4 million against liabilities of $2.5 million, while net cash used in operating activities was $1.5 million. The balance sheet’s total assets of $4.0 million included only $1.4 million in cash, meaning the company’s working capital is thinner than a bioreactor’s stainless steel walls. The filing’s language is precise; the numbers are brutal. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/2010788/000149315226030205/form8-k.htm)

Exozymes bills itself as enabling a paradigm shift in chemical production, offering AI-enhanced exozymes that can be produced in bioreactors from inexpensive feedstocks such as glucose. The company’s technology page describes enzyme platforms that deliver scalable, ready-to-use exozymes, and its press clippings rail highlights a Genesis Mission grant from the U.S. Department of Energy and the launch of a subsidiary, NCTx, aimed at unlocking a compound for gut and liver health. These are real milestones, yet none of them appear on the income statement yet. The platform story is vivid; the revenue story is absent. (source: Technology page, https://exozymes.com/technology; press clippings rail, https://exozymes.com/blog/tag/press-clippings; DOE Genesis Mission grant image, https://exozymes.com/hubfs/GenesisMissionGrant.jpg)

The company’s 10-Q for 31 March 2026 discloses research and development expense of $1.1 million, and capital expenditure of just $57,604, a figure so small it reads like a rounding error in a slide deck otherwise dominated by grand visions. Net cash used in operating activities was $1.5 million, and the company’s cash position fell to $1.4 million while liabilities rose to $2.5 million. The filing labels stockholders’ equity at $1.5 million, a figure that places the company perilously close to the thin red line of negative tangible net worth. Shareholder dilution is visible in the numbers: the diluted share count rose from 8.2 million at the end of December 2025 to 8.5 million at 31 March 2026, and the company registered additional shares for sale in two separate 424B5 filings in June-one for 1,000,000 shares, another for 2,350,000 shares-while the latest 10-Q confirms the diluted share base remains 8.5 million. The optics are unmistakable: the company is issuing shares to fund operations rather than to execute commercial rollout. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/2010788/000149315226030205/form8-k.htm; 424B5 (2026-06-08), https://www.sec.gov/Archives/edgar/data/2010788/000149315226027611/form424b5.htm; 424B5 (2026-06-30), https://www.sec.gov/Archives/edgar/data/2010788/000149315226031284/form424b5.htm)

The company’s SEC filings can be tracked via its EDGAR index and submissions JSON, both of which confirm a raft of recent 8-K and 424B5 filings through June and July 2026. These documents are the primary evidence base for the company’s operations, financing, and disclosures, and they show a company in fundraising mode rather than scale-up mode. The filings do not include revenue, gross profit, or customer metrics, so the commercial progress behind the enzymatic platform remains unquantified in the public record. (source: SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=2010788; SEC submissions JSON, https://data.sec.gov/submissions/CIK0002010788.json)

The company’s product page and press rail highlight a DOE Genesis Mission grant and the launch of NCTx, a subsidiary targeting gut and liver health compounds. These are tangible developments, yet none of them translate to revenue or cash generation in the 10-Q. The platform story is compelling; the accounts are sobering. The tension sits squarely on whether the company can convert its technology narrative into commercial traction before the cash runway runs out. (source: Technology page, https://exozymes.com/technology; press clippings rail, https://exozymes.com/blog/tag/press-clippings; ARCHIVE rail, https://exozymes.com/blog/tag/archive)